Renal Cell Carcinoma

Renal cell carcinoma (RCC, also known as hypernephroma) is a kidney cancer that originates in the lining of the proximal convoluted tubule, the very small tubes in the kidney that filter the blood and remove waste products.
What is Renal Cell Carcinoma?

Renal cell carcinoma, also called hypernephroma, is a cancer of the kidneys that forms in the proximal convoluted tubule. In the UK, it is the eighth most common cancer among adults, affecting 9,300 people every year.

Read More

Overview

Feature Articles

Latest Renal Cell Carcinoma News and Research

New $1.4M grant supports innovative kidney cancer treatment strategy

New $1.4M grant supports innovative kidney cancer treatment strategy

Gut microbiome found to play key role in chronic disease progression

Gut microbiome found to play key role in chronic disease progression

MD Anderson launches new institute for advancing cell therapy

MD Anderson launches new institute for advancing cell therapy

Copper accumulation linked to aggressive growth of kidney cancer

Copper accumulation linked to aggressive growth of kidney cancer

Mapping tumor microenvironments: Uncovering spatial subclones for improved cancer treatment

Mapping tumor microenvironments: Uncovering spatial subclones for improved cancer treatment

Molecular chaperones as key players in tumor suppressor stability

Molecular chaperones as key players in tumor suppressor stability

Non-invasive imaging technique can accurately detect clear-cell renal cell carcinoma

Non-invasive imaging technique can accurately detect clear-cell renal cell carcinoma

Trial finds no benefit of adding nivolumab to tivozanib for advanced kidney cancer

Trial finds no benefit of adding nivolumab to tivozanib for advanced kidney cancer

Belzutifan shows promise in treating advanced renal cell carcinoma

Belzutifan shows promise in treating advanced renal cell carcinoma

Review explores potential for improved use of anti-angiogenic agents in cancer therapy

Review explores potential for improved use of anti-angiogenic agents in cancer therapy

Individualized neoantigen cancer therapy demonstrates safety and efficacy in early trials

Individualized neoantigen cancer therapy demonstrates safety and efficacy in early trials

MD Anderson and Summit Therapeutics partner to accelerate ivonescimab development

MD Anderson and Summit Therapeutics partner to accelerate ivonescimab development

Live biotherapeutic product can improve clinical outcomes for patients with kidney cancer

Live biotherapeutic product can improve clinical outcomes for patients with kidney cancer

Assessing clinical benefit and safety in trial waivers for treatment-refractory cancers

Assessing clinical benefit and safety in trial waivers for treatment-refractory cancers

Breakthrough biomarker predicts recurrence risk in clear cell renal cancer

Breakthrough biomarker predicts recurrence risk in clear cell renal cancer

New WHO classification of kidney tumors integrates molecular diagnostics

New WHO classification of kidney tumors integrates molecular diagnostics

Macrophages play an unexpected role in the complicated obesity-cancer connection

Macrophages play an unexpected role in the complicated obesity-cancer connection

Wistar scientists develop Persistent Multivalent T Cell Engager for advanced kidney cancer

Wistar scientists develop Persistent Multivalent T Cell Engager for advanced kidney cancer

Study reveals no survival benefit from systemic therapy in very advanced solid tumors

Study reveals no survival benefit from systemic therapy in very advanced solid tumors

New PET imaging agent shows promise in visualizing lesions in clear cell renal cell cancer patients

New PET imaging agent shows promise in visualizing lesions in clear cell renal cell cancer patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.